<DOC>
	<DOCNO>NCT01331148</DOCNO>
	<brief_summary>Vitamin D deficiency ( VDD ) common among African American adolescent adult US , ten time higher see Caucasians . VDD also quite common sickle cell disease ( SCD ) . Both VDD SCD cause chronic pain , compression fracture , muscle weakness . The investigator believe VDD may contribute poor musculoskeletal health chronic pain see pediatric SCD . In study , investigator aim show child adolescent SCD chronic pain low level vitamin D compare without chronic pain . The investigator also aim determine clinical characteristic SCD patient related vitamin D status . About 60 subject ( 7 21 year old ) enrol study , 30 chronic pain 30 without chronic pain . The investigator assess baseline characteristic include vitamin D level , bone turnover rate ( measure C telopeptide blood level [ CTx ] ) , marker inflammation oxidative stress level blood , baseline hemoglobin laboratory parameter , presence abnormal bone chest x-ray , pulmonary function , opioid analgesic use , overall muscle strength , quality life depression . To evaluate impact vitamin D replacement baseline characteristic , investigator randomize subject receive either placebo high dose vitamin D 6 week time investigator evaluate overall vitamin D status , muscle bone health , depression , quality life , pain status use opioid pain medication , inflammation oxidative status compare treatment high dose vitamin D. The investigator give—at cost subjects—a daily supplement provide recommend daily allowance calcium vitamin D contain 500mg Calcium 200IU vitamin D subject throughout study period . Subjects study 7 month five six study visit .</brief_summary>
	<brief_title>Vitamin D Sickle Cell</brief_title>
	<detailed_description>Nearly 43 % African American adult 53-70 % African American adolescent US vitamin D deficiency ( VDD ) , ten time see Caucasians . VDD also quite common sickle cell disease ( SCD ) prevalence rate 65-100 % . Pain hallmark symptom SCD account majority SCD morbidity . Some patient SCD develop debilitate chronic pain unclear etiology unsatisfactory response treatment . Both VDD SCD cause chronic pain , compression fracture myopathy . We hypothesize VDD implicate poor musculoskeletal health chronic pain SCD . Therefore aim [ 1 ] demonstrate pediatric sickle cell patient high rate VDD chronic pain low level vitamin D compare without chronic pain [ 2 ] evaluate musculoskeletal health , pain status , opioid analgesic use , depression quality life SCD patient without chronic pain determine presence severity VDD associate severe clinical phenotype [ 3 ] demonstrate administration replacement dose vitamin D correct VDD , improve musculoskeletal health ameliorate chronic pain . An additional aim project [ 4 ] evaluate describe correlate vitamin D status serum level inflammatory cytokine , marker oxidative stress vitamin D receptor polymorphism SCD patient without chronic pain . We evaluate 60 SCD subject age 7-21 year ( 30 chronic pain 30 without chronic pain ) VDD determine specific baseline characteristic include 25 ( OH ) D level , bone turnover rate measure C telopeptide serum level ( CTx ) , opioid analgesic use , neuromuscular strength , evidence skeletal complication chest radiograph , depression quality life , serum level inflammatory cytokine oxidative status characteristic vitamin D receptor ( VDR ) . These characteristic compare chronic pain without chronic pain . We 30 day run observation period baseline pain status determine daily pain diary report . All subject randomly assign receive vitamin D replacement therapy placebo six week prospectively follow six month . All subject give daily recommend daily allowance ( RDA ) calcium vitamin D form soft chew contain 500 mg calcium 200 IU vitamin D throughout study period . The primary endpoint change serum 25 ( OH ) D CTx level opioid analgesic use ( mg/kg morphine equivalent ) . Secondary endpoint include change pain status document diary , depression score , quality life score , neuromuscular strength change serum cytokine level marker oxidative stress . In study hypothesize VDD either contribute exacerbates sickle cell chronic pain correct VDD SCD result decrease pain , depression opioid analgesic use ; improvement musculoskeletal health ; well reduction degree inflammation oxidative stress . This pilot study preparation large prospective trial evaluate role VDD pathobiology SCD pain musculoskeletal health .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>sickle cell genotype include SS , SB0thal , SC , SB+Thal Age 721 year old Last PRBC transfusion &gt; 30 day prior chronic renal failure chronic liver disease recent hospitalization &lt; 14 day history malignancy serum calcium level define protocol section D 2.2 treatment concommitant medication define section D 2.2 protocol know malabsorption short gut syndrome condition associate poor GI absorption patient currently high dose vitamin D therapy</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>vitamin D</keyword>
	<keyword>pediatrics</keyword>
	<keyword>pain</keyword>
</DOC>